Cambridge women’s health company focused on early detection and surveillance of ovarian cancer in genetically high-risk populations
Cambridge women’s health company focused on early detection and surveillance of ovarian cancer in genetically high-risk populations. Its flagship ROCA (Risk of Ovarian Cancer Algorithm) product combines a blood test with algorithmic risk assessment for women with BRCA1 or BRCA2 mutations. The technology was evaluated in prospective clinical studies and acquired by GENinCode in 2022.